我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 university of massachusetts, inc.
相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1894
已完成
4
66.7%
终止
2
33.3%
暂无批准数据
- MassBiologics of UMass Medical School has initiated the first human clinical trial of Lyme PrEP, a pre-exposure prophylaxis using a single monoclonal antibody that could prevent Lyme disease. - The trial has enrolled 66 volunteers in Nebraska to evaluate safety and pharmacology, with researchers hoping to determine how long the protective antibody remains in circulation after administration. - Unlike traditional vaccines, Lyme PrEP provides immediate protection upon injection and targets Borrelia bacteria in tick guts before transmission, potentially offering a solution to a disease that affects approximately 476,000 Americans annually.
